{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Merrimack+Pharmaceuticals", "query": { "sponsor": "Merrimack Pharmaceuticals" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Merrimack+Pharmaceuticals&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-05T12:50:43.221Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02399137", "title": "A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "MM-141", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2015-05", "completion_date": "2018-08", "has_results": false, "last_update_posted_date": "2018-09-18", "last_synced_at": "2026-10-05T12:50:43.221Z", "location_count": 47, "location_summary": "Gilbert, Arizona • Anaheim, California • Fullerton, California + 40 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redondo Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02399137" }, { "nct_id": "NCT03076372", "title": "A Study Evaluating MM-310 in Patients With Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Urothelial Carcinoma", "Gastric Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Ovarian Cancer", "Pancreatic Ductal Adenocarcinoma", "Prostate Adenocarcinoma", "Non-small Cell Lung Cancer", "Small Cell Lung Cancer", "Triple Negative Breast Cancer", "Endometrial Carcinoma", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "MM-310", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2017-02-22", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2018-02-27", "last_synced_at": "2026-10-05T12:50:43.221Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • San Francisco, California • Rochester, Minnesota + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03076372" }, { "nct_id": "NCT01304784", "title": "A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER-2 Gene Amplification" ], "interventions": [ { "name": "Cisplatin, Capecitabine, Trastuzumab and MM-111", "type": "DRUG" }, { "name": "Lapatinib +/- Trastuzumab and MM-111", "type": "DRUG" }, { "name": "Paclitaxel, Trastuzumab and MM-111", "type": "DRUG" }, { "name": "Lapatinib, trastuzumab, paclitaxel, and MM-111", "type": "DRUG" }, { "name": "Docetaxel, trastuzumab and MM-111", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2011-01", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2015-12-16", "last_synced_at": "2026-10-05T12:50:43.221Z", "location_count": 15, "location_summary": "Denver, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 12 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01304784" }, { "nct_id": "NCT01447225", "title": "Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2011-10", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2016-09-14", "last_synced_at": "2026-10-05T12:50:43.221Z", "location_count": 4, "location_summary": "Lafayette, Indiana • Buffalo, New York • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Lafayette", "state": "Indiana" }, { "city": "Buffalo", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01447225" }, { "nct_id": "NCT01520389", "title": "Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Colorectal Cancer", "Squamous Cell Head and Neck Cancer", "Non Small Cell Lung Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "MM-151", "type": "DRUG" }, { "name": "MM-151 + irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2012-01", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2018-03-21", "last_synced_at": "2026-10-05T12:50:43.221Z", "location_count": 4, "location_summary": "Aurora, Colorado • Lafayette, Indiana • Buffalo, New York + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Buffalo", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01520389" }, { "nct_id": "NCT01451632", "title": "A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Squamous Cell Head and Neck Cancer", "Non-small Cell Lung Cancer", "Triple Negative Breast Cancer", "Other Tumors With EGFR Dependence" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2011-10", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-09-08", "last_synced_at": "2026-10-05T12:50:43.221Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01451632" }, { "nct_id": "NCT02387216", "title": "A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "NSCLC", "Adenocarcinoma", "Heregulin" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elevation Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2015-02-01", "completion_date": "2019-01-02", "has_results": true, "last_update_posted_date": "2021-10-12", "last_synced_at": "2026-10-05T12:50:43.221Z", "location_count": 17, "location_summary": "Tucson, Arizona • Los Angeles, California • Santa Rosa, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02387216" }, { "nct_id": "NCT01733004", "title": "A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "MM-141", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2012-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-08-04", "last_synced_at": "2026-10-05T12:50:43.221Z", "location_count": 3, "location_summary": "Marietta, Georgia • Boston, Massachusetts • Detroit, Michigan", "locations": [ { "city": "Marietta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01733004" }, { "nct_id": "NCT00911898", "title": "A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Her2 Amplified Solid Tumors", "Metastatic Breast Cancer" ], "interventions": [ { "name": "MM-111", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2009-06", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2015-01-13", "last_synced_at": "2026-10-05T12:50:43.221Z", "location_count": 4, "location_summary": "Los Angeles, California • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00911898" }, { "nct_id": "NCT00147329", "title": "Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "MM-093", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2005-09", "completion_date": "2006-07", "has_results": false, "last_update_posted_date": "2007-02-23", "last_synced_at": "2026-10-05T12:50:43.221Z", "location_count": 2, "location_summary": "Dallas, Texas • Salt Lake City, Utah", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00147329" } ] }